The Strength of PPI HC
PPi HC provides its clients with a “one-stop shop” for market access. Our team’s international, cross-functional experience enables us to provide the support needed throughout the development and commercialisation processes, from early investment decisions, through optimal development decisions in assessing whether a candidate is able to achieve access and funding at a suitable price based on the data which can be developed in its support, right through to launch planning, launch facilitation and support on post-launch lifecycle price modulation and responding to market environment changes.
Regardless of the technology, the country or the disease area, there are certain universal considerations that must be considered around value, evidence, affordability and technology viability. Having provided support over 15 years and on over 400 assignments, our team is fully conversant with such dynamics, as well as country nuances where there are special considerations which need to be factored in to planning and evaluation decisions, such as the use of health economics and Health Technology Assessments, impacts and approaches around domestic and international reference pricing, different payer appraisal mechanisms and regulations and positioning and value messaging. In all our work, PPi can be relied upon to being our experience of all such matters to bear in order to provide our clients with the very best support possible.
About
TESTIMONIALS
“With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.”
Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.
“I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.”
Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma
“I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project.”
Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals
“Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!”
Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals
